Company Description
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company.
It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms.
Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.
The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.
The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs.
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024.
The company was founded in 2014 and is headquartered in Baltimore, Maryland.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Ian Rhodes CPA |
Contact Details
Address: 855 N. Wolfe Street, Suite 623 Baltimore, Maryland 21205 United States | |
| Phone | 856 848 8698 |
| Website | tnfpharma.com |
Stock Details
| Ticker Symbol | TNFA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001321834 |
| ISIN Number | US62856X2018 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Ian Rhodes CPA | Interim Chief Financial Officer |
| Robert Schatz | Investor Relations Officer |
| Dr. Jenna Brager M.S., Ph.D., R.N. | Executive Vice President of Drug Development |
| Dr. Mitchell Glass M.D. | President, Chief Medical Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2024 | 10-Q | Quarterly Report |
| Aug 14, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 12, 2024 | EFFECT | Notice of Effectiveness |
| Aug 12, 2024 | 424B3 | Prospectus |
| Aug 8, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Jul 26, 2024 | 8-K | Current Report |
| Jul 26, 2024 | 8-K | Current Report |
| Jul 1, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 24, 2024 | 8-K | Current Report |